Judicial Advocacy Initiative


Taking the Cancer Fight to the Courts

This initiative identifies lawsuits and regulatory actions that impact the fight against cancer and files "friend of the court" briefs or comments to advocate on behalf of cancer patients and survivors, and all people touched by this terrible disease.  The work accomplished by the Judicial Advocacy Initiative is made possible by law firms who are recruited by ACS CAN and who donate services to support its mission.

Initiative Priorities

Court decisions can have a major impact on the fight against cancer. Issues range from the employment rights of cancer patients to the tobacco industry's efforts to circumvent federal law. The JAI Initiative takes the fight against cancer to the courts, protecting the interests of the cancer community. 

Our Supporters

The JAI receives pro bono assistance from nine law firms:  Anderson & Kreiger, Brown Goldstein Levy, Dentons, K&L Gates, Hogan Lovells, Kilpatrick Townsend, King & Spalding, Morrison & Foerster LLP, and Zuckerman Spaeder. Their donated services leverage a multi-sector partnership for the common good. They provide specialized expertise in a wide range of areas, from writing comments to regulatory agencies that govern medical research to tobacco control litigation. Their commitment to JAI indicates that respected professionals in the legal establishment believe the program can make a difference.

Commemorating a Decade of Judicial Advocacy

In September 2018 we celebrated the 10th anniversary of the Judicial Advocacy Initiative (JAI). Read the full blog post to learn more.


Access to Care

July 26, 2021

ACS CAN advocated for expansion throughout the legislative process in Missouri, including playing a key role in its adoption via a ballot initiative that amended the state constitution to provide for it.

February 26, 2021

ACS CAN and 14 other health groups filed a “friend of the court” or amicus brief at the Supreme Court of the United States (SCOTUS) opposing state imposition of work or community engagement requirements for Medicaid beneficiaries.

Tobacco Litigation

October 18, 2021

The Food and Drug Administration (FDA) issued a marketing denial order (MDO) to Triton for flavored e-cigarette products that included Jimmy the Juice Man, Strawberry Astronaut, and Chew Clouds Sour Grape, finding these products not in the interest of public health, which forces them off the mark

September 27, 2021

ACS CAN supports banning menthol flavor in tobacco products as part of a comprehensive flavor ban.  Support of this ban included filing a citizens' petition at the FDA with other health groups in 2013, and supplementing that petition with updated scientific data in January of 2021.

October 20, 2020

ACS CAN and the American Cancer Society are helping defend the Food and Drug Administration (FDA)’s final rule requiring graphic warnings on cigarette packages and advertisements by filing amicus curiae briefs in parallel federal lawsuits challenging the rule.

Healthy Eating and Active Living

April 16, 2018

Sugary drinks contribute to obesity, which is clearly associated with an increased risk of cancer development and recurrence, as well as decreased risk of survival, for many cancers. The city of Philadelphia enacted a tax on soda that was challenged in court.

October 31, 2017

San Francisco passed an ordinance requiring advertisers of sugar-sweetened beverages to place a warning on specific types of advertisements stating that the product "contributes" to obesity, diabetes, and tooth decay.

Quality of Life

April 10, 2013

Cancer patients and survivors deserve a workplace free from discrimination. To that end, ACS CAN responded to an EEOC request for comments on its regulations implementing the Americans with Disabilities Act (ADA) Amendments of 2008.

Medical Research

May 24, 2013

The Office of Human Research Protections at the Department of Health and Human Services spent years considering changes to the Common Rule, which governs the conduct of medical research funded by 15 different federal agencies.